Sloning BioTechnology GmbH / Frankfurt Stock Exchange / MorphoSys AG / INKEF Capital / MorphoSys’s Growing Proprietary Portfolio MorphoSys AG / BioGeneration Ventures / Lanthio Pharma B.V. / /
Country
Germany / Netherlands / /
Currency
EUR / / /
Event
FDA Phase / Company Listing Change / Funding / M&A / /
IndustryTerm
pharmaceutical industry / antibody library technology / antibody technology / biopharmaceutical / lanthipeptide technology / treatment of cancer / human healthcare / treatment for various fibrotic diseases / pharmaceutical partners / healthcare products / biopharmaceutical start-ups / therapeutic applications / /
MedicalCondition
Fibrotic Diseases / rheumatoid arthritis / diabetic nephropathy / Alzheimer’s disease / cancer / specific disease / /
Person
Simon Moroney / Heinz Schwer / Jens Holstein / Dirk Kersten / Alexandra Goller / Jessica Rush / / /
Position
Chief Financial Officer / Candidate for Fibrotic Diseases / Claudia Gutjahr-Löser Head of Corporate Communications / Director Corporate Communications & IR Alexandra Goller / Chief Executive Officer / Manager Corporate Communications & IR Jessica Rush / leader / Managing Director / Manager Corporate Communications & IR Tel / Manager Corporate Communications & IR / Director Corporate Communications & IR / /
Product
LP2 / Series A / HuCAL / Acquires Peptide / /
Technology
antibodies / antibody technology / antibody library technology / drug development / lanthipeptide technology / /
Media Release Martinsried/Munich, Germany, and Groningen, The Netherlands, May 7, 2015 MorphoSys Acquires Peptide Therapeutic Company Lanthio Pharma Acquisition Adds Novel Candidates Including Pre-IND Candidate for Fibro